• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics

Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics

by Sarah Moniz | Aug 15, 2018

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

by Sarah Moniz | Aug 15, 2018

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

by Adam | Oct 22, 2016

Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf
Highly Immunogenic Vaccine For Prevention and Therapy of Malignant Mesothelioma

Highly Immunogenic Vaccine For Prevention and Therapy of Malignant Mesothelioma

by Adam | Oct 21, 2016

Tregitopes: The active ingredient in IVIG-mediated tolerance induction?

Tregitopes: The active ingredient in IVIG-mediated tolerance induction?

by Adam | Oct 21, 2016

« Older Entries

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline